PHAR
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Pharming announces U.S. FDA acceptance and Priority Review of the sNDA for lower-dose Joenja to treat children with APDSSep 26, 2026
- Pharming reports positive Phase 2 topline results for leniolisib in primary immunodeficiencies with immune dysregulation, accepted as a late-breaking abstract at ESID 2026Sep 22, 2026
- Pharming launched Joenja (leniolisib) commercially in Japan for adults and children aged four and older with APDSAug 13, 2026
- Pharming announced FDA acceptance of its sNDA resubmission for Joenja in children with APDSJun 4, 2026
- European Commission grants approval for Pharming’s Joenja as the first APDS treatment in the EUMay 23, 2026